semaglutide and cardiac risk GLP-1 receptor agonists can reduce the of adverse cardiovascular events in pts with diabetes. Whether the GLP-1 receptor agonist can also reduce cardiovascular risk in pts with overweight or obesity VisualAbstract: Semaglutide Improves Outcomes in

The outcome is fewer stalled intakes, clearer expectations, and a smoother baseline start

Heart palpitations during semaglutide treatment are a real concern for some patients

The grim reality when you stop GLP1s cold turkey GLP1s help you lose weight because they curb appetite, so when you stop suddenly, hunger and calorie intake skyrocket The result

Weight loss drugs can cost thousands per year without insurance

After a few years of injectable dominance, oral formulations are emerging as a game-changer for adherence and ease of use thanks to their lack of cold-chain requirement, but also a game-changer for their ability to unlock the long-term maintenance opportunity [14]